3,5,5-trimethylcyclohex-3-en-1-one

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: Test procedure in accordance with generally accepted scientific standards and described in sufficient detail

Data source

Reference

Reference 1

Reference Type:

other: thesis

Title:

Contribution a l'etude analytique toxicologique et biochimique de l'isophorone.

Author:

Dutertre-Catella H

Year:

1976

Bibliographic source:

Universite Rene Descartes, Paris

Reference 2

Reference Type:

other: OECD SIDS

Title:

3,5,5-Trimethylcyclohex-2-enone (Isophorone), CAS No. 78-59-1

Author:

OECD SIDS

Year:

2003

Bibliographic source:

SIDS Initial Assessment Report for SIAM 16

Materials and methods

Test guideline

Qualifier:

equivalent or similar to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

GLP compliance:

not specified

Test type:

standard acute method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

3,5,5-trimethylcyclohex-2-enone

EC Number:

201-126-0

EC Name:

3,5,5-trimethylcyclohex-2-enone

Cas Number:

78-59-1

IUPAC Name:

3,5,5-trimethylcyclohex-2-en-1-one

Details on test material:

- Origin: Elf Atochem S.A.

Test animals

Species:

rabbit

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Weight at study initiation: ca 2.5 kg

Administration / exposure

Type of coverage:

occlusive

Vehicle:

unchanged (no vehicle)

Details on dermal exposure:

REMOVAL OF TEST SUBSTANCE
- Time after start of exposure: after 24 hours, unresorbed quantity determined

Duration of exposure:

24 hours

Doses:

9200; 13850; 23000; 23000; 32300 mg

No. of animals per sex per dose:

6

Control animals:

yes

Details on study design:

- Duration of observation period following administration: 14 days
- Frequency of observations: daily

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

1 200 mg/kg bw

Remarks on result:

other: according to the authors, as cited in OECD SIDS

Mortality:

Number of deaths and time at each dose:
9.2 g dose (0.6 ± 0.4 g/kg absorbed): none
13.85 g dose (0.75 ± 0.5 g/kg): 2 after 6 and 12 hours, resp.
23 g dose (1.7 ± 0.9 g/kg): 3 after 3, 4, and 5 hours, resp.
23 g dose (2.85 ± 1.3 g/kg): 3 after 4, 6, and 48 hours, resp.
32.3 g dose (2.5 ± 1 g/kg): 6 after 2.5, 4x4, 5 hours, resp.

Clinical signs:

other: Accelerated breathing, prostration, narcosis, death (mostly within 6 hours) or recovery. The intensity of the erythema varied between animals. Recovery of the skin was not always complete within the postexposure period. Doses at which clinical signs appea

Any other information on results incl. tables

RS-Freetext:
MORTALITY
Dose      absorbed      deaths    timepoint
[mg]      [mg/kg]                  [hours]
---------------------------------------------------
9200      600 ± 400      0/6      -
13850     750 ± 500      2/6      6, 12
23000    1700 ± 900      3/6      3, 4, 5
23000    2850 ± 1300     3/6      4, 6, 48
32300    2500 ± 1000     6/6      2.5, 4 x 4, 5

LD50: 1200 mg/kg bw (according to OECD SIDS)

CLINICAL SIGNS
Animals showed accelerated breathing, prostration and narcosis.
Death occured mostly within 6 hours, but survivors recovered.
The intensity of the erythema varied between animals, recovery of the  skin was not always complete within the postexposure period.
Doses at which clinical signs appeared were not defined in the study.

POTENTIAL TARGET ORGANS
None identified (except skin).

SEX-SPECIFIC DIFFERENCES
None identified.